Kane will advance strategic priorities and advance Solrikitug, its lead asset, in Phase II trials and prepare for Phase III.

Karuna Therapeutics is a biopharmaceutical company driven to discover, develop, and deliver transformative medicines for people living with psychiatric and neurological conditions.

Karuna Therapeutics, Inc. and GFB, LLC, assignee of the Goldfinch Bio assignment estate, today announced their entry into an exclusive license agreement under which Karuna will obtain global ...

Below is a summary of how these 12 analysts rated Karuna Therapeutics over the past 3 months. The greater the number of bullish ratings, the more positive analysts are on the stock and the greater ...

What happened Shares of Karuna Therapeutics (KRTX) were up 14% late Wednesday morning on news regarding the company's lead therapy.

Bristol Myers agrees to buy Boston’s Karuna Therapeutics in a $14 billion deal Karuna has applied for FDA approval of a drug to treat schizophrenia.

Below is a summary of how these 5 analysts rated Karuna Therapeutics over the past 3 months. The greater the number of bullish ratings, the more positive analysts are on the stock and the greater ...

Karuna Therapeutics, Inc. stock had >8x gain after my Buy rating before successful Phase 3 trial data for KarXT in treating schizophrenia. Read more here.

We discussed Karuna Therapeutics, Inc. (NASDAQ:KRTX) in another article and shared the list of best high risk high reward stocks to buy.

Karuna Therapeutics' KarXT has shown promising efficacy in phase III studies and has a unique mechanism of action compared to traditional antipsychotics. Find out why KRTX stock is a Buy.

Drugmaker Bristol Myers BMY-0.19%decrease; red down pointing triangle Squibb reached a deal to buy neuroscience-drug developer Karuna Therapeutics for $14 billion. Under the terms, Bristol would ...